Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from Truist Financial

Truist Financial reissued their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report released on Monday morning, Benzinga reports. Truist Financial currently has a $120.00 price objective on the stock.

Other analysts have also issued reports about the company. Citigroup decreased their price target on Intellia Therapeutics from $31.00 to $29.00 and set a neutral rating on the stock in a research note on Friday, May 10th. BMO Capital Markets raised their price target on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an outperform rating in a research note on Friday, May 10th. Wedbush reaffirmed a neutral rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. StockNews.com raised Intellia Therapeutics to a sell rating in a research note on Friday, May 10th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $69.00.

Intellia Therapeutics Stock Up 1.2 %

NTLA opened at $23.19 on Monday. The firm has a market cap of $2.24 billion, a P/E ratio of -4.33 and a beta of 1.84. Intellia Therapeutics has a 52 week low of $19.37 and a 52 week high of $46.50. The business’s fifty day simple moving average is $23.74 and its 200 day simple moving average is $26.36.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. The firm had revenue of $28.94 million for the quarter, compared to analyst estimates of $15.60 million. As a group, equities analysts expect that Intellia Therapeutics will post -4.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors have recently made changes to their positions in NTLA. Blue Trust Inc. bought a new position in Intellia Therapeutics during the fourth quarter valued at about $26,000. Signaturefd LLC boosted its stake in Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock valued at $49,000 after buying an additional 751 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Intellia Therapeutics by 35.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock valued at $93,000 after buying an additional 793 shares in the last quarter. Spire Wealth Management boosted its stake in Intellia Therapeutics by 3,789.0% during the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock valued at $119,000 after buying an additional 3,789 shares in the last quarter. Finally, EntryPoint Capital LLC boosted its stake in Intellia Therapeutics by 61.1% during the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after buying an additional 1,563 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.